早孕期联合筛查子痫前期:PAPP-A与PlGF的比较
本研究比较了早孕期联合筛查中血清PAPP-A与PlGF对子痫前期、小于胎龄儿和21三体的筛查性能。结果显示,在基于母体特征、血压和子宫动脉多普勒的筛查方案中,使用PAPP-A或PlGF对子痫前期和SGA的检测无显著临床差异。
要点
- 在早孕期联合筛查中,PAPP-A与PlGF对早产子痫前期的筛查性能无显著差异(AUC 0.78 vs 0.79,P=0.55)。
- 对足月子痫前期、SGA和21三体的筛查性能,PAPP-A与PlGF同样无显著差异。
- 在公共医疗环境中,可沿用现有PAPP-A方案实施子痫前期联合筛查,无需更改协议。
核心结论
- 在常规早孕期联合筛查中,使用PlGF或PAPP-A对子痫前期或SGA的检测无显著临床差异。
研究设计与样本
- 回顾性研究,嵌套于接受早孕期联合筛查的妊娠队列,共1094名妇女检测PAPP-A,其中82例子痫前期、111例SGA、53例两者兼有、94例21三体;1066/1094名妇女获取了PlGF水平。
主要发现
- 子痫前期孕妇血清PlGF中位MoM为1.0(IQR 0.8-1.4),显著低于对照组1.2(IQR 0.9-1.5),P<0.01。
- SGA孕妇PlGF中位MoM为1.0(IQR 0.8-1.3),显著低于对照组,P<0.001。
- 21三体孕妇PlGF中位MoM为0.6(IQR 0.5-0.9),显著低于对照组,P<0.0001。
- 早产子痫前期筛查AUC:PAPP-A 0.78 vs PlGF 0.79,P=0.55;足月子痫前期AUC:两者均为0.74,P=0.60。
- 使用PAPP-A与PlGF对SGA或21三体的联合筛查灵敏度和特异度无显著差异。
关键数值与推荐
- 早产子痫前期高风险(≥1/50)孕妇每日接受150 mg阿司匹林,并在28和36周进行胎儿生长扫描,从40周起提供择期分娩。
临床怎么用
- 在公共医疗环境中,可继续使用PAPP-A进行早孕期联合筛查,无需更改现有协议。
- 生物标志物的选择应基于性能与测量要求之间的良好平衡,视具体环境而定。
局限性
- PlGF为回顾性从储存的早孕期血清样本中定量,部分样本缺失。
- 研究期间高风险孕妇使用了阿司匹林,可能影响子痫前期患病率,但校正后结论不变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the screening performance of serum pregnancy-associated plasma protein-A (PAPP-A) vs placental growth factor (PlGF) in routine first-trimester combined screening for pre-eclampsia (PE), small-for-gestational age (SGA) at birth and trisomy 21. METHODS: This was a retrospective study nested in pregnancy cohorts undergoing first-trimester combined screening for PE and trisomy 21 using The Fetal Medicine Foundation (FMF) algorithm based on maternal characteristics, nuchal translucency thickness, PAPP-A, free beta-human chorionic gonadotropin, blood pressure and uterine artery Doppler. Women at high risk for preterm PE (≥ 1 in 50) received 150 mg of aspirin per day, underwent serial fetal growth scans at 28 and 36 weeks and were offered elective birth from 40 weeks of gestation. PlGF was quantified retrospectively from stored surplus first-trimester serum samples. The performance of combined first-trimester screening for PE and SGA using maternal history, blood pressure, uterine artery pulsatility index and either PAPP-A or PlGF was calculated. Similarly, the performance of combined first-trimester screening for trisomy 21 was calculated using either PAPP-A or PlGF in addition to maternal age, nuchal translucency thickness and free beta-human chorionic gonadotropin. RESULTS: Maternal serum PAPP-A was assayed in 1094 women, including 82 with PE, 111 with SGA (birth weight < 10th centile), 53 with both PE and SGA and 94 with fetal trisomy 21. PlGF levels were obtained retrospectively from 1066/1094 women. Median serum PlGF multiples of the median was significantly lower in pregnancies with PE (1.0 (interquartile range (IQR), 0.8-1.4); P < 0.01), SGA (1.0 (IQR, 0.8-1.3); P < 0.001) and trisomy 21 (0.6 (IQR, 0.5-0.9); P < 0.0001) compared to in controls (1.2 (IQR, 0.9-1.5)). There was no significant difference in the performance of first-trimester screening using PAPP-A vs PlGF for either preterm PE (area under the receiver-operating-characteristics curve (AUC), 0.78 vs 0.79; P = 0.55) or term PE (AUC, 0.74 vs 0.74; P = 0.60). These findings persisted even after correction for the effect of targeted aspirin use on the prevalence of PE. Similarly, there were no significant differences in sensitivity and specificity of combined screening for SGA or trisomy 21 when using PAPP-A vs PlGF. CONCLUSIONS: Using either PlGF or PAPP-A in routine first-trimester combined screening based on maternal characteristics, blood pressure and uterine artery Doppler does not make a significant clinical difference to the detection of PE or SGA. Depending on the setting, biomarkers should be chosen to achieve a good compromise between performance and measurement requirements. This pragmatic clinical-effectiveness study suggests that combined screening for PE can be implemented successfully in a public healthcare setting without changing current protocols for the assessment of PAPP-A in the first trimester. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Noël L, Guy GP, Jones S, et al. Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor? Ultrasound Obstet Gynecol. 2021. PMID: 33998078. doi:10.1002/uog.23669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。